TD Cowen made an adjustment to Danaher Corporation's (NYSE:DHR) financial outlook by reducing the price target from $315.00 to $260.00. Despite this change, the firm has maintained a Buy rating on the ...

Learn more about whether Belden Inc. or Fabrinet is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The Diagnostic Couch market is poised for steady growth in the coming years, driven by the increasing demand for advanced medical equipment ...

Pathology Lab Equipment Market Growth Secured At 6.37% CAGR To Achieve 25.0 Billion USD By 2032 Leica Biosystems The Global Pathology Lab Equipment market is driven by several key factors, including ...

The global in vitro diagnostics (IVD) market is projected to grow steadily at a CAGR of 4.8%, increasing from USD 81.3 ...

Discover some of the top technology companies building innovative and game-changing products specifically with the future in mind.

From a margin perspective, Danaher's operations should eventually improve once top-line growth rebounds. With that operating leverage-related margin expansion, we expect Danaher's adjusted EPS to grow ...

Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited 2024 consolidated financial results for the year ending 31 ...